Cao Rui-Yuan, Xiao Jun-Hai, Cao Bin, Li Song, Kumaki Yohichi, Zhong Wu
National Engineering Research Center for Strategic Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing, PR China.
Antivir Chem Chemother. 2014 Dec 16;23(6):237-40. doi: 10.3851/IMP2672.
A novel reassortant avian-origin influenza A (H7N9) virus was isolated from respiratory specimens obtained from three patients and was identified as H7N9 in China. Antiviral agents are required to treat patients with avian influenza H7N9 virus infection.
In this study, we assessed the antiviral potential of oseltamivir, peramivir, favipiravir (T-705), amantadine and rimantadine against novel reassortant avian-origin influenza H7N9 virus in vitro.
All three avian influenza H7N9 virus strains were sensitive to oseltamivir, peramivir and favipiravir (T-705), but resistant to amantadine and rimantadine.
Our data show a pattern of antiviral sensitivity for this novel H7N9 strain of influenza that suggests the compounds oseltamivir, peramivir and favipiravir should be useful for therapy.
从三名患者的呼吸道标本中分离出一种新型重配禽源甲型流感（H7N9）病毒，该病毒在中国被鉴定为H7N9。治疗H7N9禽流感病毒感染的患者需要抗病毒药物。
在本研究中，我们评估了奥司他韦、帕拉米韦、法匹拉韦（T-705）、金刚烷胺和金刚乙胺对新型重配禽源甲型流感H7N9病毒的体外抗病毒潜力。
所有三种H7N9禽流感病毒株对奥司他韦、帕拉米韦和法匹拉韦（T-705）敏感，但对金刚烷胺和金刚乙胺耐药。
我们的数据显示了这种新型H7N9流感病毒株的抗病毒敏感性模式，表明奥司他韦、帕拉米韦和法匹拉韦这些化合物可用于治疗。
